(Q35629569)

9 August 2017

1 reference

title

Gene therapy approaches for osteogenesis imperfecta (English)

1 reference

9 August 2017

0 references

osteogenesis imperfecta

0 references

author name string

Niyibizi C

1

1 reference

9 August 2017

Wang S

2

1 reference

9 August 2017

Mi Z

3

1 reference

9 August 2017

Robbins PD

4

1 reference

9 August 2017

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

11

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

408-416

1 reference

Orthopedic applications of gene therapy

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Genetic heterogeneity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Type V osteogenesis imperfecta: a new form of brittle bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Diminished type I collagen synthesis and reduced alpha 1(I) collagen messenger RNA in cultured fibroblasts from patients with dominantly inherited (type I) osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Seminars in medicine of the Beth Israel Hospital, Boston. Mutations in collagen genes as a cause of connective-tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Tracing the pathway between mutation and phenotype in osteogenesis imperfecta: isolation of mineralization-specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Therapeutic approaches to bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Marrow stromal cells as stem cells for nonhematopoietic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Multilineage potential of adult human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

21 January 2018

Mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osteogenesis imperfecta: prospects for molecular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

A mutation-independent therapeutic strategem for osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Ribozymes: structure, function, and potential therapy for dominant genetic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Structural characteristics of cross-linking sites in type V collagen of bone. Chain specificities and heterotypic links to type I collagen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Functional results of operation in osteogenesis imperfecta: elongating and nonelongating rods

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Potential of gene therapy for treating osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Strategems in vitro for gene therapies directed to dominant mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

In vivo expression of human growth hormone by genetically modified murine bone marrow stromal cells and its effect on the cells in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302199

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302199

1 reference

9 August 2017

1 reference